Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
17a-(2-propionoxyethyl)-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 100% inhibition
17a-allyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 99% inhibition
17a-ethyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 100% inhibition
17a-methyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 99% inhibition
2,6,4'-methoxybenzophenone
from Anemarrhena aspholoides rhizomes
3-keto-Delta4-abiraterone
-
-
cis-hinokiresinol
from Anemarrhena aspholoides rhizomes
mangiferin
a 1,3,6,7-tetrahydroxyxanthone-C2-beta-D-glucoside, from Anemarrhena aspholoides rhizomes, directly inhibits SRD5A2 binding to a complex of enzyme and substrate
(+/-)-LY191704
-
i.e. (4aS,10aR)-7-chloro-1-methyl-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-one, non-steroidal, most potent benzoquinoline mimicing 4-azasteroid inhibitors, and specific for isozyme 5alphaR-1, IC50 is 30 nM
(10bR)-8-chloro-4,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 49% inhibition at 0.02 mM
(10bR)-8-chloro-4,5,10b-trimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 57% inhibition at 0.029 mM
(10bR)-8-chloro-5,10b-dimethyl-4a,5,6,10b-tetrahydrophenanthridin-2(1H)-one
-
isoform II, 42% inhibition at 0.03 mM
(1E,4E,6E)-1,7-bis(3-hydroxy-4-methoxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1,7-bis(3-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1,7-bis(4-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1,7-diphenylhepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1-(2-chlorophenyl)-7-phenylhepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1-(3-hydroxy-4-methoxyphenyl)-7-(3-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1-(3-nitrophenyl)-7-phenylhepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1-(4-hydroxy-3-methoxyphenyl)-7-(3-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-1-(4-methoxyphenyl)-7-phenylhepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-7-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,4E,6E)-7-[3-(cycloprop-2-en-1-yloxy)phenyl]-1-(2-hydroxyphenyl)hepta-1,4,6-trien-3-one
-
-
(1E,6E)-1,7-bis(3,4-dihydroxyphenyl)hepta-1,6-diene-3,5-dione
-
-
(2E)-3-(4-hydroxy-3-methoxycyclohexa-1,5-dien-1-yl)-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]prop-2-enamide
-
-
(2E)-3-(4-hydroxy-3-methoxycyclohexa-1,5-dien-1-yl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide
-
-
(2E)-3-(4-hydroxy-3-methoxycyclohexa-1,5-dien-1-yl)-N-[2-(4-methoxyphenyl)ethyl]prop-2-enamide
-
-
(4aS)-7-chloro-4a-methyl-2,3,4,4a-tetrahydrophenanthrene-2-carboxylic acid
-
-
(4aS,10bS)-4,10b-dimethyl-8-[(E)-2-naphthylylvinyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 6 nM, isoform II, 50% inhibition at 0.00134 mM
(4aS,10bS)-4,10b-dimethyl-8-[(E)-2-phenylvinyl]-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 6 nM, isoform II, 50% inhibition at 0.0014 mM
(4aS,10bS)-4,8-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 11 nM
(4aS,10bS)-8-(2-furyl)-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 59 nM, isoform II, 50% inhibition above 10 nM
(4aS,10bS)-8-bromo-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 35 nM
(4aS,10bS)-8-chloro-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 60 nM
(4aS,10bS)-8-chloro-4,10b-dimethyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 17 nM
(4aS,10bS)-8-chloro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 8 nM, isoform II, 50% inhibition above 0.01 mM
(4aS,10bS)-8-fluoro-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 35 nM
(4aS,10bS)-8-methoxy-4-methyl-1,4,4a,5,6,10b-hexahydrobenzo[f]quinolin-3(2H)-one
-
isoform I, 50% inhibition at 120 nM
(4E,6E)-1-(4-hydroxyphenyl)-7-phenylhepta-4,6-dien-3-one
-
-
(4R)-4,8-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 312 nM
(4R)-8-chloro-4-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 141 nM
(4S)-4,8-dimethyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 137 nM
(6E)-1-(4-hydroxyphenyl)-7-phenylhept-6-en-3-one
-
-
(6R)-8-chloro-6-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 188 nM
1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 298 nM
1-methyl-5-(4-(2-phenylacetyl)phenyl)pyridin-2(1H)-one
-
61% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
17-diisopropylcarbamoyl-2-androsten-3-carboxylate
-
-
17-diisopropylcarbamoyl-3,5-androstadien-3-carboxylate
-
-
17-diisopropylcarbamoyl-3-androsten-3-carboxyate
-
-
17-diisopropylcarbamoyl-androstan-3-carboxylate
-
-
17-tert-butylcarbamoyl-3,5-androstadien-3-carbaldehyde
-
-
17-tert-butylcarbamoyl-3,5-androstadien-3-carboxylate
-
dead-end inhibition versus testosterone
17-tert-butylcarbamoyl-3,5-androstadien-3-ol
-
-
17a-(2-propionoxyethyl)-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 8.5% inhibition
17a-allyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 0.4% inhibition
17a-ethyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 32.3% inhibition
17a-methyl-17-oxo-17a-aza-D-homo-3,5-androstadien-3-oic acid
0.01 mM, 18.9% inhibition
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3 20-dione
-
-
17alpha-p-bromophenylcarbamoyloxy-4-pregnen-3,20-dione
-
-
17alpha-phenylcarbamoyloxy-4-pregnen-3,20-dione
-
-
17beta-(N-tert-butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
-
-
17beta-Carbamoyl-1,3,5(10)-estratriene-3-carboxylic acids
-
formation of enzyme-NADP+-inhibitor complex
17beta[3-(N-4-bromophenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-chlorophenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-ethoxyphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-ethylphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-methoxyphenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-phenyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
-
17beta[3-(N-4-tolyl)tetrahydrooxazin-2-on-6-yl]androst-4-en-3-one
-
slight inhibition
2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
2,5-dihydroxy-1,4-benzoquinone
-
inhibitor isolated from Thai mangrove Avicennia marina
-
2-(16-(acetylthio)hexadecanamido)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate
-
43% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
2-(2-(16-(acetylthio)hexadecanamido)ethoxy)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate
-
33% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
2-(2-hydroxypropan-2-yl)-2,3-dihydronaphtho[2,3-b]furan-4,9-dione
-
inhibitor isolated from Thai mangrove Avicennia marina
-
2-acetyl-2,3-dihydronaphtho[2,3-b]furan-4,9-dione
-
inhibitor isolated from Thai mangrove Avicennia marina
-
2-acetylnaphtho[2,3-b]furan-4,9-dione
-
inhibitor isolated from Thai mangrove Avicennia marina
-
2-hydroxy-4-[(4E,6E)-3-oxo-7-phenylhepta-4,6-dien-1-yl]phenyl acetate
-
-
2-methoxy-5-[(6E)-3-methoxy-7-phenylhept-6-en-1-yl]benzene-1,4-diol
-
-
2-propanoylnaphtho[2,3-b]furan-4,9-dione
-
inhibitor isolated from Thai mangrove Avicennia marina
-
3-Androstene-3-carboxylic acids
-
-
3-keto-5alpha-abiraterone
-
-
3-keto-Delta4-abiraterone
-
-
3beta-(3'-oxapentanoyloxy)-androst-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
3beta-acetoxyandrost-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
3beta-hexanoyloxyandrost-5-en-17-one
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
4,6,8-trimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 15.8 nM
4,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 20 nM
4-(1-[4-[acetyl(methyl)amino]-3-methylphenyl]-1-ethylpropyl)-2-methylphenyl diethylcarbamate
-
22% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]-3-methylphenyl]-1-ethylpropyl)phenyl diethylcarbamate
-
25% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)-2-methylphenyl diethylcarbamate
-
56% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl 4-methylpiperazine-1-carboxylate
-
17% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl azepane-1-carboxylate
-
70% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl azocane-1-carboxylate
-
20% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl bis(1-methylethyl)carbamate
-
72% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl bis(1-methylpropyl)carbamate
-
22% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dibenzylcarbamate
-
51% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dibutylcarbamate
-
32% inhibition at 0.001 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl diethylcarbamate
-
57% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dimethylcarbamate
-
29% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl dipropylcarbamate
-
77% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl morpholine-4-carboxylate
-
15% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl piperidine-1-carboxylate
-
68% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-ethylpropyl)phenyl pyrrolidine-1-carboxylate
-
57% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-methylethyl)phenyl diethylcarbamate
-
16% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]-1-propylbutyl)phenyl diethylcarbamate
-
27% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cyclobutyl)phenyl diethylcarbamate
-
16% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cycloheptyl)phenyl diethylcarbamate
4-(1-[4-[acetyl(methyl)amino]phenyl]cyclopentyl)phenyl diethylcarbamate
-
5% inhibition at 0.01 mM
4-(2-[5-[(diphenylmethyl)carbamoyl]-1-benzofuran-2-yl]phenoxy)butanoic acid
-
isoform I, 50% inhibition at 310 nM, isoform II, 50% inhibition above 0.1 mM
4-(2-[6-[(diphenylmethyl)carbamoyl]-1-benzofuran-2-yl]phenoxy)butanoic acid
-
isoform I, 50% inhibition at 62 nM, isoform II, 50% inhibition at 270 nM
4-(3-(4-(N-methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate
-
competitive inhibitor
4-(4'-formylphenoxy)benzoic acid
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.007 mM
4-(biphenyl-4'-yloxy)phenylacetic acid
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.00006 mM
4-(biphenyl-4'-yloxy)phenylformic acid
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.000006 mM
4-(N-(diphenyl)acetyl-4-piperidinyloxy)benzoic acid
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.0013 mM
4-(N-(diphenyl)carbamoyl-4-piperidinyloxy)benzoic acid
-
pH 5.5, 37°C, DU145 cells, 10% inhibition at 0.01 mM, BPH tissue, 68% inhibition at 0.01 mM
4-(N-(tert-butyloxycarbonyl)-4-piperidinyloxy)benzoic acid
-
pH 5.5, 37°C, DU145 cells, 2% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.0078 mM
4-(N-adamantanoyl-4-piperidinyloxy)benzoic acid
-
pH 5.5, 37°C, DU145 cells, 7% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.00043 mM
4-Androsten-3-one-17beta-carboxylic acid
-
competitive
4-carboxy-4'-(N,N-dicyclohexyl)-aminobiphenyl
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.0047 mM, DU145 cells, 44% inhibition at 0.001 mM
4-carboxy-4'-(N,N-diisobutyl)-aminobiphenyl
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.004 mM, DU145 cells, 16% inhibition at 0.001 mM
4-carboxy-4'-(N,N-diisopropyl)-aminobiphenyl
-
pH 5.5, 37°C, BPH tissue, 15% inhibition at 0.001 mM, DU145 cells, 9% inhibition at 0.001 mM
4-carboxy-4'-(N,N-diphenyl)-aminobiphenyl
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.00233 mM, DU145 cells, 28% inhibition at 0.001 mM
4-carboxy-4'-(N-adamantyl)-aminobiphenyl
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.0019 mM, DU145 cells, 16% inhibition at 0.001 mM
4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 185 nM
4-methyl-5,6-dihydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 1400 nM
4-[(6E)-3-oxo-7-phenylhept-6-en-1-yl]phenyl acetate
-
-
4-[1-[4-(acetylamino)-3-methylphenyl]-1-ethylpropyl]-2-methylphenyl diethylcarbamate
-
17% inhibition at 0.01 mM
4-[2-(6-[[bis(4-fluorophenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 50 nM, isoform II, 50% inhibition at 340 nM
4-[2-(6-[[bis(4-methoxyphenyl)methyl]amino]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 42 nM, isoform II, 50% inhibition at 480 nM
4-[2-(6-[[bis(4-methoxyphenyl)methyl]carbamoyl]-1-benzofuran-2-yl)phenoxy]butanoic acid
-
isoform I, 50% inhibition at 130 nM, isoform II, 50% inhibition at 930 nM
4-[3-[(2,2-diphenyl-1,3-benzodioxol-5-yl)oxy]-2-methyl-1H-indol-1-yl]butanoic acid
-
isoform I, 50% inhibition at 10 nM, isoform II, 50% inhibition at 6300 nM
6,8-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 14.3 nM
7-bromo-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
7-chloro-2,4a,9,10-tetrahydrophenanthrene-2-carboxylic acid
-
-
8-bromo-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 60 nM, isoform I
8-chloro-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 49 nM
8-chloro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 460 nM, isoform I
8-chloro-1-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 204 nM
8-chloro-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 459 nM
8-chloro-4,5-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 15.6 nM
8-chloro-4,6-dimethyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 8.5 nM
8-chloro-4-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 7.6 nM
8-chloro-4-methyl-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 30 nM, isoform I
8-chloro-5-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 346 nM
8-chloro-6-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 14.4 nM
8-fluoro-1,4,5,6-tetrahydrobenzo[f]quinolin-3(2H)-one
-
50% inhibition at 600 nM, isoform I
8-methyl-1,2,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 376 nM
8-methyl-4,4a,5,6-tetrahydro-3H-pyrido[1,2-a]quinolin-3-one
-
isoform I, 50% inhibition at 176 nM
alpha-4-azasteroids
-
substitution of finasteride N-group by 6-azasteroids increased the rate of inhibition of type-1 5-alpha-reductases
avicequinone C
-
inhibitor isolated from Thai mangrove Avicennia marina
-
benzoquilizin-3-ones
-
diverse, mimics of 10-azasteroids, overview, structure-activity relationships
benzoquinolines
-
compounds as mimics of 4-azasteroid inhibitors, diverse, overview, compounds derived from 6-azasteroids, overview
bisdemethoxycurcumin
-
22.2% inhibition at 0.3 mM
curcumin
-
complete inhibition at 0.3 mM
dehydroepiandrosterone
-
good in vitro inhibitory activity, but compound does not bind to the androgen receptors
demethoxycurcumin
-
complete inhibition at 0.3 mM
deoxycorticosterone acetate
-
competitive
docosanol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
estradiol
-
in female genital skin fibroblasts
FK143
-
i.e. 4-[3-(3-[[bis-(4-isobutyl-phenyl)-methyl]amino]-benzoyl)-indol-1-yl]-butyric acid, a non-steroidal bi-substrate inhibitor
Lapachol
-
inhibitor isolated from Thai mangrove Avicennia marina
lauric acid
-
isoform 1, 50% inhibition at 0.0167 mM, isoform 2, 50% inhibition at 0.0186 mM
lauric acid ethyl ester
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
Lawsone
-
inhibitor isolated from Thai mangrove Avicennia marina
linoleic acid
-
isoform 1, 50% inhibition at 0.013 mM, isoform 2, 50% inhibition at 0.035 mM
LY306089
-
a non steroid, non-competitive inhibitor of type I 5alpha-reductase in DU145 cells
myristic acid
-
isoform 2, 50% inhibition at 0.004 mM
N,N-bis(1-methylethyl)-4-(1-methyl-2-oxo-1,2-dihydroquinolin-6-yl)benzamide
-
isoform I, 50% inhibition at 510 nM, isoform II, 9% inhibition at 0.01 mM
N,N-dicyclohexyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.0067 mM, DU145 cells, 4% inhibition at 0.001 mM
N,N-diisobutyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 46% inhibition at 0.01 mM
N,N-diisopropyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide
-
8% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-2-(4-(1-methyl-6-oxopiperidin-3-yl)phenoxy)acetamide
-
6% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy)acetamide
-
3% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N,N-diisopropyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 36% inhibition at 0.01 mM, DU145 cells, 4% inhibition at 0.001 mM
N,N-diphenyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.00085 mM
N-(1-adamantanoyl)piperdine-4-(2-methoxybenzyliden-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 10% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.0012 mM
N-(1-adamantanoyl)piperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 20% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.00021 mM
N-(3,3-diphenyl)propanoylpiperidine-4-(benzylidene-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 8% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.0011 mM
N-(dicyclohexyl)acetylpiperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 12% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.000011 mM
N-(dicyclohexyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 5% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.00013 mM
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-3-carboxylic acid)
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.0007mM
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-4-acetic acid)
-
pH 5.5, 37°C, DU145 cells, 6% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.000006 mM
N-(dicyclohexyl)acetylpiperidine-4-(benzylidene-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 46% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.00006 mM
N-(diphenyl)acetylpiperidine-4-(2-fluorobenzylidene-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 2% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.00041 mM
N-(diphenyl)acetylpiperidine-4-(2-methoxybenzylidene-4-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 8% inhibition at 0.01 mM, BPH tissue, 50% inhibition at 0.0035 mM
N-(diphenyl)acetylpiperidine-4-(benzylidene-3-carboxylic acid)
-
pH 5.5, 37°C, DU145 cells, 6% inhibition at 0.01 mM, BPH tissue, 57% inhibition at 0.01 mM
N-(diphenyl)acetylpiperidine-4-(benzylidene-4-acetic acid)
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.000075 mM
N-adamantyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.00038 mM
N-allyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide
-
6% inhibition of type 1 steroid 5alpha reductase at 0.01 mM
N-allyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy)acetamide
-
8% inhibition of type 1 steroid 5alpha reductase at 0.01 mM and 12% inhibition of type 2 steroid 5alpha reductase at 0.01 mM
N-cyclohexyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.0023 mM
N-phenyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.001 mM
N-tert-butyl-4-(4'-carboxyphenoxy)benzamide
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.0028 mM
naphtho[2,3-b]furan-4,9-dione
-
inhibitor isolated from Thai mangrove Avicennia marina
non-steroidal bi-substrate inhibitors
-
several, structures, overview
-
oleic acid
-
isoform 1, 50% inhibition at 0.004 mM, isoform 2, 50% inhibition above 0.1 mM
oleic acid ethyl ester
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
ONO-3805
-
a non-steroidal bi-substrate inhibitor
palmitic acid
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
penta-O-galloyl-beta-D-glucose
-
from Thea sativa, inhibits the expression of androgen receptor and reduce secretion of prostate-specific antigen in LNCaP prostate cancer cells
progesterone
-
competitive
sitosterol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
SKF105657
-
a steroidal type II 5alpha-reductase specific inhibitor
stearic acid
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
steroid carboxylic acid compounds
-
diverse, tricyclic aryl acid mimics of, overview
theaflavin-3,3'-digallate
-
from Thea sativa, inhibits the expression of androgen receptor and reduce secretion of prostate-specific antigen in LNCaP prostate cancer cells
tocopherol
-
isoform 1, 50% inhibition above 0.1 mM, isoform 2, 50% inhibition above 0.1 mM
Unsaturated 3-carboxysteroids
-
-
-
finasteride
-
4-(1-[4-[acetyl(methyl)amino]phenyl]cycloheptyl)phenyl diethylcarbamate
-
46% inhibition at 0.01 mM
4-(1-[4-[acetyl(methyl)amino]phenyl]cycloheptyl)phenyl diethylcarbamate
-
25% inhibition at 0.01 mM
4-azasteroids
-
-
4-azasteroids
-
competitive inhibition
4-methyl-4-azasteroids
-
competitive
-
4-methyl-4-azasteroids
-
4-MA is a 90-fold more potent inhibitor than finasteride in the DU 145 cell-line
-
dutasteride
-
-
dutasteride
-
inhibits both isozymes, used in treatment of benign protstate hyperplasia, reduction of serum dihydrotestosterone levels
dutasteride
-
slow, time-dependent inhibitor, more efficient than finasteride
dutasteride
-
0.5 mg/day, dual 5alpha-reductase inhibitor
dutasteride
-
0.5 mg/day, inhibitor of type 1 and type 2 5alpha reductase
dutasteride
-
90% inhibition of type-2 and type-1 5alpha-reductases at clinical dosage of 0.5 mg/day
dutasteride
-
dual 5alpha-reductase inhibitor, 45fold more effective in inhibiting type 1 5alpha-reductase and 2fold more effective in inhibiting type 2 5alpha-reductase than finasteride
dutasteride
-
inhibitor of isoenzymes 5-alpha-reductase type 1 and type 2
dutasteride
-
treatment with 0.5 mg daily for 1 year leads to reduced enzyme activity
finasteride
-
-
finasteride
-
17-beta-N-tert-butylcarbonyl-4-aza-5alpha-androstan-1-en-3-one is a time-dependent, apparently irreversible inhibitor of 5alpha-reductases, but does not fully inhibit the activity of 5alpha-reductase in vivo
finasteride
-
replacement of residues 26-29 (AVFA) from isozyme 1 with residues 21-24 (GALA) from isozyme 2 increases the resistance to finasteride, what confirms that residues 26-29 from isozyme 1 are involved in the inhibitor/substrate binding but suggest residues 21-29 from isozyme 2 are not. More findings indicate that residues 15-17 of human 5 alpha-reductase 2 participate in inhibitor/substrate binding
finasteride
-
4-azasteroid, specific for isozyme 5alphaR-2, used in treatment of benign protstate hyperplasia, reduction of serum dihydrotestosterone levels
finasteride
-
i.e. 17beta-(N-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one
finasteride
-
pH 5.5, 37°C, BPH tissue, 50% inhibition at 0.000003 mM, DU145 cells, 50% inhibition at 0.00041 mM
finasteride
-
slow, time-dependent inhibitor
finasteride
-
5 mg/day, selective inhibitor of isoenzyme 5-alpha-reductase type 2
finasteride
-
5.0 mg/day, effective inhibitor of type 2 5alpha-reductase
finasteride
-
5.0 mg/day, inhibits type 2 5alpha-reductase
finasteride
-
5alphaR2 inhibitor
finasteride
-
70% inhibition of type-2 5alpha-reductase at clinical dosage of 5.0 mg/day
finasteride
-
treatment with 5 mg daily for 1 year leads to reduced enzyme activity
finasteride
-
type 2 5alpha-reductase inhibitor
MK386
-
steroidal inhibitor
MK386
-
potent inhibitory effect on 5alphaR1
additional information
inhibitory effects on SRD5A2 of Chinese medicine herb extracts, of Anemarrhena aspholoides rhizomes, Pellodendron amurense bark, and Cinnamomum cassia bark, collected in China, Korea, and Japan, overview
-
additional information
-
inhibitory effects on SRD5A2 of Chinese medicine herb extracts, of Anemarrhena aspholoides rhizomes, Pellodendron amurense bark, and Cinnamomum cassia bark, collected in China, Korea, and Japan, overview
-
additional information
-
-
-
additional information
-
kinetic inhibition mechanism of steroidal and non-steroidal inhibitors, competitive steroidal inhibitors, type A or type B, act with a substrate-like or a product-like transition state, type C uncompetitive steroidal inhibitors, overview
-
additional information
-
synthesis of diverse steroidal tetrahydrooxazin-2-ones as potential inhibitors of the enzyme, IC50 of inhibitory compounds, overview
-
additional information
-
no inhibition of type 2 steroid 5alpha reductase at 0.01 mM N,N-diisopropyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide, N-allyl-2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamide, N,N-diisopropyl-2-(4-(1-methyl-6-oxopiperidin-3-yl)phenoxy)acetamide, 1-methyl-5-(4-(2-phenylacetyl)phenyl)pyridin-2(1H)-one, N,N-diisopropyl-2-(4-(2-methyl-4-oxo-3,4-dihydropyridin-1(2H)-yl)phenoxy) acetamide, 2-(16-(acetylthio)hexadecanamido)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate, and 2-(2-(16-(acetylthio)hexadecanamido)ethoxy)ethyl 6-(2-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenoxy)acetamido)hex-4-enoate
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3-oxo-5alpha-steroid 4-dehydrogenase (acceptor) deficiency
5alpha-reductase activity in the prostate.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
5-Alpha-reductase type 2 deficiency. A new case in the Spanish population.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
A new deletion of the 5 alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
A novel mutation of the 5alpha-reductase type 2 gene in two unrelated Egyptian children with ambiguous genitalia.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Accuracy of Urinary Etiocholanolone/Androsterone Ratio as Alternative to Serum Testosterone/Dihydrotestosterone Ratio for Diagnosis of 5 Alpha-reductase Type 2 Deficiency Patients and Carriers in Indonesia.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Androgens, androgen receptors, and male gender role behavior.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Characterising SRD5A2 Gene Variants in 37 Indonesian Patients with 5-Alpha-Reductase Type 2 Deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Detection of the G34R mutation in the 5 alpha reductase 2 gene by allele specific PCR and its linkage to the 89L allele among Egyptian cases.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Disorders of androgen action.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Fetal Genotype-Phenotype Sex Discordance: A Case of 5-Alpha-Reductase Deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Giant seminoma in a patient with 5 alpha-reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Molecular basis of androgen insensitivity.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
New Territory for an Old Disease: 5-Alpha-Reductase Type 2 Deficiency in Bulgaria.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Testicular histological and immunohistochemical aspects in a post-pubertal patient with 5 alpha-reductase type 2 deficiency: case report and review of the literature in a perspective of evaluation of potential fertility of these patients.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
Unexpected ethical dilemmas in sex assignment in 46,XY DSD due to 5-alpha reductase type 2 deficiency.
3-oxo-5alpha-steroid 4-dehydrogenase (nadp+) deficiency
[The importance of DNA analysis in the diagnosis of steroid 5-alpha-reductase deficiency]
Acne Vulgaris
Clinical application of 5alpha-reductase inhibitors.
Acne Vulgaris
Epristeride (SmithKline Beecham).
Adenocarcinoma
5alpha-reductase and 17beta-hydroxysteroid dehydrogenase expression in epithelial cells from hyperplastic and malignant human prostate.
Adenocarcinoma
Expression of aromatase and 5-alpha-reductase genes in endometrial adenocarcinoma.
Adenocarcinoma
Immunochemical detection of 5 alpha-reductase in human serum.
Alopecia
5 alpha-reductase type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro.
Alopecia
A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
Alopecia
Androgens and alopecia.
Alopecia
Management of male pattern hair loss.
Androgen-Insensitivity Syndrome
Molecular basis of androgen insensitivity.
Azoospermia
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Breast Neoplasms
A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women.
Breast Neoplasms
Dutasteride affects progesterone metabolizing enzyme activity/expression in human breast cell lines resulting in suppression of cell proliferation and detachment.
Breast Neoplasms
The dialectic role of progesterone.
Breast Neoplasms
The V89L polymorphism in the 5-alpha-reductase type 2 gene and risk of breast cancer.
Carcinoma
Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome.
Carcinoma, Transitional Cell
Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome.
Coloboma
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Dermatitis
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Dermatitis, Atopic
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Disorder of Sex Development, 46,XY
5 alpha-reduced androgens play a key role in murine parturition.
Disorder of Sex Development, 46,XY
5-alpha-reductase 2 deficiency in a woman with primary amenorrhea.
Disorder of Sex Development, 46,XY
Disorders of androgen action.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency.
Disorder of Sex Development, 46,XY
Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2).
Disorder of Sex Development, 46,XY
Molecular basis of androgen insensitivity.
Disorder of Sex Development, 46,XY
Natural mutagenesis study of the human steroid 5 alpha-reductase 2 isozyme.
Dwarfism
5alpha-Reductase activity in Lycopersicon esculentum: cloning and functional characterization of LeDET2 and evidence of the presence of two isoenzymes.
Endometriosis
Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis.
Hirsutism
Clinical application of 5alpha-reductase inhibitors.
Hirsutism
Management of hirsutism.
Hyperprolactinemia
Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats.
Hypospadias
5alpha-reductase type 2 mutations are present in some boys with isolated hypospadias.
Hypospadias
Disorders of androgen action.
Hypospadias
Expression of the androgen receptor and 5 alpha-reductase type 2 in the developing human fetal penis and urethra.
Hypospadias
Steroid 5alpha-reductase 1 polymorphisms and testosterone/dihydrotestosterone ratio in male patients with hypospadias.
Hypospadias
Two novel mutations of SRD5A2 gene in Indonesian siblings with clinical 5-alpha-reductase deficiency.
Insulin Resistance
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
Neoplasms
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Neoplasms
Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells.
Neoplasms
Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Neoplasms
Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.
Neoplasms
Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue.
Neoplasms
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
Neoplasms
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Neoplasms
Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma.
Neoplasms
Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome.
Neoplasms
Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells.
Neoplasms
SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer.
Neoplasms
The dialectic role of progesterone.
Neoplastic Processes
Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues.
Oligospermia
Steroid 5alpha-reductase 2 gene melting polymorphisms in male subjects with azoospermia or oligospermia.
Optic Atrophy
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Ovarian Neoplasms
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Peripheral Arterial Disease
Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease.
Prostatic Hyperplasia
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Prostatic Hyperplasia
Epristeride (SmithKline Beecham).
Prostatic Hyperplasia
Establishment of a novel model for studying the effects of extracts of Chinese herb medicine on human type II 5alpha-reductase in vitro.
Prostatic Neoplasms
5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
Prostatic Neoplasms
A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland.
Prostatic Neoplasms
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
Prostatic Neoplasms
Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.
Prostatic Neoplasms
Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Prostatic Neoplasms
Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Prostatic Neoplasms
Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Prostatic Neoplasms
Hormonal carcinogenesis.
Prostatic Neoplasms
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Prostatic Neoplasms
Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Prostatic Neoplasms
SRD5A2 V89L polymorphism and prostate cancer risk: A meta-analysis.
Prostatic Neoplasms
Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer.
Prostatic Neoplasms
Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study.
Prostatic Neoplasms
SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer.
Prostatic Neoplasms
The role of molecular genetics in chemoprevention studies of prostate cancer.
Retinal Dystrophies
Early-onset retinal dystrophy and chronic dermatitis in a girl with an undiagnosed congenital disorder of glycosylation (SRD5A3-CDG).
Seminoma
Giant seminoma in a patient with 5 alpha-reductase type 2 deficiency.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Holt, D.A.; Levy, M.A.; Oh, H.J.; Erb, J.M.; Heaslip, J.I.; Brandt, M.; Lan-Hargest, H.Y.; Metcalf, B.W.
Inhibition of steroid 5alpha-reductase by unsaturated 3-carboxysteroids
J. Med. Chem.
33
943-950
1990
Homo sapiens, Rattus norvegicus
brenda
Holt, D.A.; Levy, M.A.; Ladd, D.L.; Oh, H.J.; Erb, J.M.; Heaslip, J.I.; Brandt, M.; Metcalf, B.M.
Steroidal A ring aryl carboxylic acids: a new class of steroid 5alpha-reductase inhibitors
J. Med. Chem.
33
937-942
1990
Homo sapiens, Rattus norvegicus
brenda
Metcalf, B.W.; Holt, D.A.; Levy, M.A.; Erb, J.M.; Heaslip, J.I.; Brandt, M.; Oh, H.J.
Potent inhibition of human steroid 5alpha-reductase (EC 1.3.1.30) by 3-androstene-3-carboxylic acids
Bioorg. Chem.
17
372-376
1989
Homo sapiens
-
brenda
Graef, V.; Golf, S.W.; Tuschen, M.
NADPH: 4-ene-3-oxosteroid-5alpha-reductase and NADH: 4-ene-3-oxosteroid-5alpha-reductase in liver microsomes of different species of animals
J. Steroid Biochem.
14
883-887
1981
Gallus gallus, Chinchilla chinchilla, Oryctolagus cuniculus, Homo sapiens, Mesocricetus auratus, Mus musculus, Rattus norvegicus, Sus scrofa
brenda
Thouvenot, D.; Morfin, R.F.
Interferences of zearalenone, zearalanol or estradiol-17beta with the steroid-metabolizing enzymes of the human prostate gland
J. Steroid Biochem.
13
1337-1345
1980
Homo sapiens
brenda
Voigt, W.; Hsia, S.I.
Further studies on testosterone 5 -reductase of human skin. Structural features of steroid inhibitors
J. Biol. Chem.
248
4280-4285
1973
Homo sapiens
brenda
Moore, R.J.; Wilson, J.D.
Steroid 5alpha-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities
J. Biol. Chem.
251
5895-5900
1976
Homo sapiens
brenda
Wallace, A.M.; Grant, J.K.
Effect of zinc on androgen metabolism in the human hyperplastic prostate
Biochem. Soc. Trans.
3
540-542
1975
Homo sapiens
brenda
Cowan, R.A.; Cook, B.; Cowan, S.K.; Grant, J.K.; Sirett, D.A.N.; Wallace, A.M.
Testosterone 5alpha-reductase and the accumulation of dihydrotestosterone in benign prostatic hyperplasia
J. Steroid Biochem.
11
609-613
1979
Homo sapiens
brenda
Tian, G.; Mook, R.; Moss, M.L.; Frye, S.V.
Mechanism of time-dependent inhibition of 5alpha-reductases by delta 1-4-azasteroids: Toward perfection of rates of time-dependent inhibition by using ligand-binding energies
Biochemistry
34
13453-13459
1995
Homo sapiens
brenda
Wigley, W.C.; Prihoda, J.S.; Mowszowicz, I.; Mendonca, B.B.; New, M.I.; Wilson, J.D.; Russel, D.W.
Natural mutagenesis study of the human steroid 5alpha-reductase 2 isozyme
Biochemistry
33
1265-1270
1994
Homo sapiens
brenda
Quemener, E.; Amet, Y.; Fournier, G.; Di Stefano, S.; Abalain, J.H.; Floch, H.H.
Glyosylated nature of testosterone 5alpha-reductase 2 purified from human prostate
Biochem. Biophys. Res. Commun.
205
296-274
1994
Homo sapiens
-
brenda
Delos, S.; Iehle, C.; Martin, M.; Raynaud, J.P.
Inhibition of the activity of basic 5alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells
J. Steroid Biochem. Mol. Biol.
48
347-352
1994
Homo sapiens, Spodoptera frugiperda
brenda
Levy, M.A.; Brandt, M.; Sheedy, K.M.; Holt, D.A.; Heaslip, J.I.; Trill, J.J.; Ryan, P.J.; Morris, R.A.; Garrison, L.M.; Bergsma, D.J.
Cloning, expression and functional characterization of type 1 and type 2 steroid 5alpha-reductase from cynomolgus monkey: comparison with human and rat isoenzymes
J. Steroid Biochem. Mol. Biol.
52
307-319
1995
Homo sapiens, Macaca fascicularis, Rattus norvegicus
brenda
Beckmann, M.W.; Wieacker, P.; Dereser, M.M.; Flecken, U.; Breckwoldt, M.
Influence of steroid hormones on 5alpha-reductase activity in female and male genital skin fibroblats in culture
Acta Endocrinol.
128
161-167
1993
Homo sapiens
brenda
Cooke, G.M.; Pothier, F.; Murphy, B.D.
The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene 5alpha-reductase activity
J. Steroid Biochem. Mol. Biol.
60
353-359
1997
Homo sapiens, Sus scrofa
brenda
Kaefer, M.; Audia, J.E.; Bruchovsky, N.; Goode, R.L.; Hsiao, K.C.; Leibovitch, I.Y.; Krushinski, J.H.; Lee, C; Steidle, C.P.; et al.
Charaterization of type I 5alpha-reductase activity in DU145 human prostatic adenocarcinoma cells
J. Steroid Biochem. Mol. Biol.
58
195-205
1996
Homo sapiens
brenda
Baxter, F.O.; Trivic, S.; Lee, I.R.
Structure-function studies of human 5alpha-reductase type 2 using site directed mutagenesis
J. Steroid Biochem. Mol. Biol.
77
167-175
2001
Homo sapiens
brenda
Lee, H.H.; Ho, C.T.; Lin, J.K.
Theaflavin-3,3'-digallate and penta-O-galloyl-beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells
Carcinogenesis
25
1109-1118
2004
Homo sapiens, Rattus norvegicus
brenda
Picard, F.; Hartmann, R.W.
N-Substituted 4-(4-carboxyphenoxy)benzamides.: Synthesis and evaluation as inhibitors of steroid 5alpha-reductase type 1 and 2
J. Enzyme Inhib. Med. Chem.
17
187-196
2002
Homo sapiens, Rattus norvegicus
brenda
Picard, F.; Barassin, S.; Mokhtarian, A.; Hartmann, R.W.
Synthesis and evaluation of 2'-substituted 4-(4'-carboxy- or 4'-carboxymethylbenzylidene)-N-acylpiperidines: highly potent and in vivo active steroid 5alpha-reductase type 2 inhibitors
J. Med. Chem.
45
3406-3417
2002
Homo sapiens, Rattus norvegicus
brenda
Raynaud, J.P.; Cousse, H.; Martin, P.M.
Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of Permixon
J. Steroid Biochem. Mol. Biol.
82
233-239
2002
Homo sapiens
brenda
Occhiato, E.G.; Guarna, A.; Danza, G.; Serio, M.
Selective non-steroidal inhibitors of 5alpha-reductase type 1
J. Steroid Biochem. Mol. Biol.
88
1-16
2004
Homo sapiens
brenda
Ranjan, M.; Diffley, P.; Stephen, G.; Price, D.; Walton, T.J.; Newton, R.P.
Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride
Life Sci.
71
115-126
2002
Homo sapiens
brenda
Shirakawa, T.; Okada, H.; Acharya, B.; Zhang, Z.; Hinata, N.; Wada, Y.; Uji, T.; Kamidono, S.; Gotoh, A.
Messenger RNA levels and enzyme activities of 5alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue
Prostate
58
33-40
2004
Homo sapiens
brenda
Woelfling, J.; Hackler, L.; Mernyak, E.; Schneider, G.; Toth, I.; Szecsi, M.; Julesz, J.; Sohar, P.; Csampai, A.
Neighboring group participation. Part 15. Stereoselective synthesis of some steroidal tetrahydrooxazin-2-ones, as novel presumed inhibitors of human 5alpha-reductase
Steroids
69
451-460
2004
Homo sapiens
brenda
Goodarzi, M.O.; Shah, N.A.; Antoine, H.J.; Pall, M.; Guo, X.; Azziz, R.
Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women
J. Clin. Endocrinol. Metab.
91
4085-4091
2006
Homo sapiens
brenda
Makridakis, N.; Reichardt, J.K.
Pharmacogenetic analysis of human steroid 5alpha reductase type II: Comparison of finasteride and dutasteride
J. Mol. Endocrinol.
34
617-623
2005
Homo sapiens
brenda
Thomas, L.N.; Lazier, C.B.; Gupta, R.; Norman, R.W.; Troyer, D.A.; OBrien, S.P.; Rittmaster, R.S.
Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer
Prostate
63
231-239
2005
Homo sapiens
brenda
Rittmaster, R.S.
5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction
Best Pract. Res. Clin. Endocrinol. Metab.
22
389-402
2008
Homo sapiens
brenda
Liu, S.; Yamauchi, H.
Different patterns of 5alpha-reductase expression, cellular distribution, and testosterone metabolism in human follicular dermal papilla cells
Biochem. Biophys. Res. Commun.
368
858-864
2008
Homo sapiens
brenda
McCarthy, A.R.; Hartmann, R.W.; Abell, A.D.
Evaluation of 4-substituted bicyclic pyridones as non-steroidal inhibitors of steroid 5alpha-reductase
Bioorg. Med. Chem. Lett.
17
3603-3607
2007
Homo sapiens
brenda
Hosoda, S.; Hashimoto, Y.
3,3-diphenylpentane skeleton as a steroid skeleton substitute: novel inhibitors of human 5alpha-reductase 1
Bioorg. Med. Chem. Lett.
17
5414-5418
2007
Homo sapiens
brenda
Carneiro, M.M.; Morsch, D.M.; Camargos, A.F.; Reis, F.M.; Spritzer, P.M.
Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis
BJOG
115
113-117
2008
Homo sapiens
brenda
Appell, R.A.
Male lower urinary tract symptoms: treatment with alpha-blockers, 5-alpha-reductase inhibitors, antimuscarinics, or a combination
Curr. Urol. Rep.
8
370-372
2007
Homo sapiens
brenda
Onen, I.H.; Ekmekci, A.; Eroglu, M.; Polat, F.; Biri, H.
The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population
DNA Cell Biol.
26
100-107
2007
Homo sapiens
brenda
Cussenot, O.; Azzouzi, A.R.; Nicolaiew, N.; Mangin, P.; Cormier, L.; Fournier, G.; Valeri, A.; Cancel-Tassin, G.
Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors
Eur. Urol.
52
1082-1087
2007
Homo sapiens
brenda
Baldinotti, F.; Majore, S.; Fogli, A.; Marrocco, G.; Ghirri, P.; Vuerich, M.; Tumini, S.; Boscherini, B.; Vetri, M.; Scommegna, S.; Rinaldi, R.; Simi, P.; Grammatico, P.
Molecular characterization of 6 unrelated Italian patients with 5alpha-reductase type 2 deficiency
J. Androl.
29
20-28
2008
Homo sapiens
brenda
Amory, J.K.; Wang, C.; Swerdloff, R.S.; Anawalt, B.D.; Matsumoto, A.M.; Bremner, W.J.; Walker, S.E.; Haberer, L.J.; Clark, R.V.
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men
J. Clin. Endocrinol. Metab.
92
1659-1665
2007
Homo sapiens
brenda
Bratoeff, E.; Sainz, T.; Cabeza, M.; Heuze, I.; Recillas, S.; Perez, V.; Rodriguez, C.; Segura, T.; Gonzales, J.; Ramirez, E.
Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5alpha-reductase
J. Steroid Biochem. Mol. Biol.
107
48-56
2007
Homo sapiens, Mesocricetus auratus
brenda
Serfling, R.; Shulman, M.; Thompson, G.L.; Xiao, Z.; Benaim, E.; Roehrborn, C.G.; Rittmaster, R.
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling
J. Urol.
177
2352-2356
2007
Homo sapiens
brenda
Tindall, D.J.; Rittmaster, R.S.
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer
J. Urol.
179
1235-1242
2008
Homo sapiens, Rattus norvegicus
brenda
Amory, J.K.; Anawalt, B.D.; Matsumoto, A.M.; Page, S.T.; Bremner, W.J.; Wang, C.; Swerdloff, R.S.; Clark, R.V.
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men
J. Urol.
179
2333-2338
2008
Homo sapiens
brenda
Assinder, S.J.
Oxytocin increases 5alpha -reductase activity of human prostate epithelial cells, but not stromal cells
Prostate
68
115-121
2008
Homo sapiens
brenda
Thevis, M.; Geyer, H.; Mareck, U.; Flenker, U.; Schaenzer, W.
Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite
Ther. Drug Monit.
29
236-247
2007
Homo sapiens
brenda
Oliveira, O.L.; Koff, W.J.; Muraro, F.; Santos, E.B.; Gomes Soares, D.F.; Trindade, V.M.
Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues
Clin. Chim. Acta
391
36-40
2008
Homo sapiens
brenda
Signorelli, S.S.; Barresi, V.; Musso, N.; Anzaldi, M.; Croce, E.; Fiore, V.; Condorelli, D.F.
Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease
J. Endocrinol. Invest.
31
1092-1097
2008
Homo sapiens (P18405), Homo sapiens (P31213), Homo sapiens
brenda
Walter, K.N.; Kienzle, F.B.; Frankenschmidt, A.; Hiort, O.; Wudy, S.A.; van der Werf-Grohmann, N.; Superti-Furga, A.; Schwab, K.O.
Difficulties in diagnosis and treatment of 5 alpha-reductase type 2 deficiency in a newborn with 46,XY DSD
Horm. Res. Paediatr.
74
67-71
2010
Homo sapiens (P31213)
brenda
Wang, X.; Liao, J.; Yin, D.; Zhan, F.; Dai, S.; Xie, G.; Sang, X.
Establishment of a novel model for studying the effects of extracts of Chinese herb medicine on human type II 5alpha-reductase in vitro.
Yakugaku Zasshi
130
1207-1214
2010
Homo sapiens (P31213), Homo sapiens
brenda
Gillespie, C.; Almli, L.; Smith, A.; Bradley, B.; Kerley, K.; Crain, D.; Mercer, K.; Weiss, T.; Phifer, J.; Tang, Y.; Cubells, J.; Binder, E.; Conneely, K.; Ressler, K.
Sex dependent influence of a functional polymorphism in steroid 5-alpha-reductase type 2 (SRD5A2) on post-traumatic stress symptoms
Am. J. Med. Genet. B Neuropsychiatr. Genet.
162
283-292
2013
Homo sapiens (P31213)
brenda
Aggarwal, S.; Thareja, S.; Bhardwaj, T.R.; Haupenthal, J.; Hartmann, R.W.; Kumar, M.
Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5alpha-reductase inhibitors: a legitimate approach
Eur. J. Med. Chem.
54
728-739
2012
Homo sapiens (P18405), Homo sapiens (P31213)
brenda
Li, J.; Ding, Z.; Wang, Z.; Lu, J.F.; Maity, S.N.; Navone, N.M.; Logothetis, C.J.; Mills, G.B.; Kim, J.
Androgen regulation of 5alpha-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention
PLoS ONE
6
e28840
2011
Homo sapiens, Homo sapiens (P31213), Homo sapiens (Q9H8P0)
brenda
Arellano, Y.; Bratoeff, E.; Garrido, M.; Soriano, J.; Heuze, Y.; Cabeza, M.
New ester derivatives of dehydroepiandrosterone as 5alpha-reductase inhibitors
Steroids
76
1241-1246
2011
Homo sapiens
brenda
Srivilai, J.; Rabgay, K.; Khorana, N.; Waranuch, N.; Nuengchamnong, N.; Wisuitiprot, W.; Chuprajob, T.; Changtam, C.; Suksamrarn, A.; Chavasiri, W.; Sornkaew, N.; Ingkaninan, K.
Anti-androgenic curcumin analogues as steroid 5-alpha reductase inhibitors
Med. Chem. Res.
26
1550-1556
2017
Homo sapiens, Homo sapiens CRL-1740
-
brenda
Srivilai, J.; Rabgay, K.; Khorana, N.; Waranuch, N.; Nuengchamnong, N.; Wisuitiprot, W.; Chuprajob, T.; Changtam, C.; Suksamrarn, A.; Chavasiri, W.; Sornkaew, N.; Ingkaninan, K.
Anti-androgenic curcumin analogues as steroid 5-alpha reductase inhibitors
Med. Chem. Res.
26
1550-1556
2017
Homo sapiens, Homo sapiens CRL-1740
-
brenda
Karnsomwan, W.; Netcharoensirisuk, P.; Rungrotmongkol, T.; De-Eknamkul, W.; Chamni, S.
Synthesis, biological evaluation and molecular docking of avicequinone C analogues as potential steroid 5alpha-reductase inhibitors
Chem. Pharm. Bull.
65
253-260
2017
Homo sapiens
brenda
Peng, H.M.; Valentin-Goyco, J.; Im, S.C.; Han, B.; Liu, J.; Qiao, J.; Auchus, R.J.
Expression in Escherichia Coli, purification, and functional reconstitution of human steroid 5alpha-reductases
Endocrinology
161
bqaa117
2020
Homo sapiens (P18405), Homo sapiens (P31213)
brenda
Gent, R.; du Toit, T.; Swart, A.C.
11alpha-Hydroxyprogesterone, a potent 11alpha-hydroxysteroid dehydrogenase inhibitor, is metabolised by steroid-5alpha-reductase and cytochrome P450 17alpha-hydroxylase/17,20-lyase to produce C11alpha-derivatives of 21-deoxycortisol and 11-hydroxyandrostenedione in vitro
J. Steroid Biochem. Mol. Biol.
191
105369
2019
Homo sapiens (P18405), Homo sapiens (P31213)
brenda
Xiao, Q.; Wang, L.; Supekar, S.; Shen, T.; Liu, H.; Ye, F.; Huang, J.; Fan, H.; Wei, Z.; Zhang, C.
Structure of human steroid 5alpha-reductase 2 with the anti-androgen drug finasteride
Nat. Commun.
11
5430
2020
Homo sapiens (P31213)
brenda